 |
|
|
| |
Most vulnerable HCV patient groups (PWID) treated with direct acting antivirals achieve high response rates and gain
quality of life - Data from the German Hepatitis C-Registry (DHC-R)
|
| |
| |
EASL 2023 June 21-24 Vienna
Stefan Christensen1,2, Albrecht Stoehr3, Gerlinde Teuber4, Jörg Petersen3, Ralph Link5, Uwe Naumann6, Christine John7, Yvonne Serfert8, Karl-Georg Simon9, Stefan Zeuzem10, Heiner
Wedemeyer8,11
|
| |
|
|
|
|
|
